Skip to content
LATEST
Business

Orthocell Reports Record US Sales of $180,000 for Nerve Repair Product

Orthocell reported record US sales for its Remplir nerve repair product in October, signaling increased market adoption and planned manufacturing capacity…

Orthocell Reports Record US Sales of $180,000 for Nerve Repair Product

Orthocell achieved record monthly sales of its Remplir nerve repair product in the United States during October, totaling 92 units and approximately $180,000 in revenue. This performance represents an 84% increase over the average monthly sales volume recorded during the first quarter of fiscal year 2027.

The growth is attributed to increased surgeon adoption, expanded hospital access through Value Assessment Committee approvals, and a larger network of distributor representatives. The company is currently scaling its manufacturing capacity to accommodate projected demand increases following the product's FDA 510(k) clearance in April 2025.

Regulatory expansion remains a primary strategic objective, with approvals in the European Union and the United Kingdom anticipated by late 2026. The firm continues to prioritize the expansion of its commercial infrastructure to support long-term market penetration in the peripheral nerve repair sector.

More stories

Latest news